Do you check IGHV mutation status in patients with newly diagnosed CLL?

Yes.

In the targeted therapy era, there are three factors that continue to have prognostic and therapeutic significance and should be checked:

• IgHV mutation status
• p53 aberrancy - requires both FISH for del17p AND mutation analysis for p53
• Complex karyotype - can be done on peripheral blood or marrow

From a therapy standpoint, we have known for some time that some patients with a mutated IgHV status appear to be cured with chemoimmunotherapy, with plateaus on curves from the CLL8 and long-term...